title: Managing atypical hemolytic uremic syndrome: chapter 2.
abstract: Licht et al. present the 2-year follow-up data of the landmark trials studying the efficacy of eculizumab in the treatment of atypical hemolytic uremic syndrome (aHUS). They report sustained improvements in hematologic parameters, continued safety, and additional improvements in kidney function with extended treatment. This report adds a layer of comfort to our care of patients with this rare disease; however, it is unlikely to be the final chapter in the treatment of aHUS.
authors.affiliation: 1] Stead Family Department of Pediatrics, University of Iowa, Iowa City, USA [2] Department of Internal Medicine, University of Iowa, Iowa City, USA.
authors.forename: Carla M
authors.initials: CM
authors.lastname: Nester
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage*; D065766:Atypical Hemolytic Uremic Syndrome / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008297:Male
chemical_list: D061067:Antibodies, Monoclonal, Humanized